The predicted targets for hsa-miR-200a include deleted in liver cancer 1 gene(DLC1), E2F transcription factor 4 (E2F4), andAHNAK nucleoprotein (desmoyokin) (AHNAK); forhsa-miR-200b: DLC1, ubiquitin-like modifier activating enzyme 6(UBA6), ubiquitin-conjugating enzyme E2I (UBE2I) andheterogeneous nuclear ribonucleoprotein A3 (HNRNPA3); for hsa-miR-200c:alpha thalassemia/mental retardation syndrome X-linked gene (ATRX),hereditary hemochromatosis (HFE), DLC1 andthrombospondin 1 (THBS) (Tables I and II). The gene discussed is HNRNPA3; the disease is hereditary hemochromatosis.